据路透,知情人士透露,诺和诺德已再次提高对肥胖症初创公司Metsera的收购出价。此举是回应辉瑞辉瑞周三对Metsera的出价提高至每股最高86.2美元,最新出价与诺和诺德最近一次公开宣布的提议相当。据了解,辉瑞对其出价设定“倒计时条款”,意味该报价将在一定时间后失效。
据路透,知情人士透露,诺和诺德已再次提高对肥胖症初创公司Metsera的收购出价。此举是回应辉瑞辉瑞周三对Metsera的出价提高至每股最高86.2美元,最新出价与诺和诺德最近一次公开宣布的提议相当。据了解,辉瑞对其出价设定“倒计时条款”,意味该报价将在一定时间后失效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.